Jorge Mestre-Ferrandiz (Jorge Mestre-Ferrándiz)

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 9

Top Topics

Antimicrobial Resistance

Decision Making

Top Venues

Applied health economics and health policy

PharmacoEconomics

This page only lists publications with an associated author ORCID identifier.

Publications

Néboa Zozaya, Javier Villaseca, Irene Fernández, Fernando Maurício Francis Abdalla, Benito Cadenas-Noreña, Miguel Ángel Ma Calleja-Hernández, Pedro Gómez-Pajuelo, Jorge Mestre-Ferrandiz, Juan Oliva, José Luis Trillo, Álvaro Hidalgo-Vega
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries. Applied health economics and health policy (2024)
Néboa Zozaya, Javier Villaseca, Irene Fernández, Fernando Maurício Francis Abdalla, Benito Cadenas-Noreña, Miguel Ángel Ma Calleja-Hernández, Pedro Gómez-Pajuelo, Jorge Mestre-Ferrandiz, Juan Oliva, José Luis Trillo, Álvaro Hidalgo-Vega
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries. Applied health economics and health policy 22 (3) (2024)
Néboa Zozaya, Javier Villaseca, Irene Fernández, Fernando Maurício Francis Abdalla, Benito Cadenas-Noreña, Miguel Ángel Ma Calleja-Hernández, Pedro Gómez-Pajuelo, Jorge Mestre-Ferrandiz, Juan Oliva, José Luis Trillo, Álvaro Hidalgo-Vega
A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries. Applied health economics and health policy 22 (3) (2024)
Michael Schlander, Karla Hernandez-Villafuerte, Chih-Yuan Cheng, Jorge Mestre-Ferrandiz, Michael Baumann
How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. PharmacoEconomics 39 (11) (2021)
David John Mott, Grace Hampson, Martin J Llewelyn, Jorge Mestre-Ferrandiz, Michael M Hopkins
Authors' Reply to Hays: "A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance". Applied health economics and health policy 18 (3) (2020)
Brendan Shaw, Jorge Mestre-Ferrandiz
Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices. PharmacoEconomics 38 (2) (2020)
David John Mott, Grace Hampson, Martin J Llewelyn, Jorge Mestre-Ferrandiz, Michael M Hopkins
A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance. Applied health economics and health policy 18 (1) (2020)
Jaime Espín, Michael Schlander, Brian B Godman, Pippa Anderson, Jorge Mestre-Ferrandiz, Isabelle Borget, Adam Hutchings, Steven Flostrand, Adam Parnaby, Claudio Jommi
Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates. Applied health economics and health policy 16 (6) (2019)
Jorge Mestre-Ferrandiz, Néboa Zozaya, Bleric Alcalá, Álvaro Hidalgo-Vega
Multi-Indication Pricing: Nice in Theory but Can it Work in Practice? PharmacoEconomics 36 (12) (2019)